Axogen マネジメント
マネジメント 基準チェック /34
Axogenの CEO はMichael Daleで、 Aug2024年に任命され、 の在任期間は 1.83年です。 の年間総報酬は$ 9.05Mで、 8.6%給与と91.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.12%を直接所有しており、その価値は$ 2.72M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.4年です。
主要情報
Michael Dale
最高経営責任者
US$9.0m
報酬総額
| CEO給与比率 | 8.58% |
| CEO在任期間 | 1.8yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 2.4yrs |
| 取締役会の平均在任期間 | 4.4yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 31
AXGN: Lower Risk Assumptions And 2026 Guidance Will Drive Upside Potential
Axogen's updated analyst price target is unchanged in this model at $50.78. Recent target increases from multiple firms are generally tied by analysts to refined discount rate assumptions and updated long term P/E expectations, rather than shifts in projected revenue growth or profit margins.ナラティブの更新 • May 04
AXGN: BLA Approval And New Market Entry Will Drive Upside Potential
Axogen's analyst price target has been raised from $41.22 to $50.78, with analysts pointing to updated assumptions around fair value, revenue growth, profit margins and recent Street research highlighting the impact of Avance Nerve Graft's BLA approval and commercial expansion opportunities. Analyst Commentary Recent Street research around Axogen clusters around the impact of Avance Nerve Graft's BLA approval, expanded market exposure and revised fair value assumptions, with a series of price target moves anchoring the discussion.分析記事 • Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
It's been a pretty great week for Axogen, Inc. ( NASDAQ:AXGN ) shareholders, with its shares surging 12% to US$41.77 in...ナラティブの更新 • Apr 18
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.ナラティブの更新 • Apr 01
AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.ナラティブの更新 • Mar 17
AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.ナラティブの更新 • Mar 03
AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.ナラティブの更新 • Feb 17
AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.ナラティブの更新 • Feb 02
AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.ナラティブの更新 • Jan 19
AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.ナラティブの更新 • Jan 04
AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.ナラティブの更新 • Dec 14
AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.ナラティブの更新 • Nov 30
AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.分析記事 • Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...ナラティブの更新 • Nov 16
AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.分析記事 • Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shares have continued their recent momentum with a 30% gain in the last month alone. The...ナラティブの更新 • Oct 31
AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.分析記事 • Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Those holding Axogen, Inc. ( NASDAQ:AXGN ) shares would be relieved that the share price has rebounded 29% in the last...新しいナラティブ • May 29
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.分析記事 • May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
Axogen, Inc. ( NASDAQ:AXGN ) shareholders that were waiting for something to happen have been dealt a blow with a 32...分析記事 • Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Axogen, Inc. ( NASDAQ:AXGN ) is a stock to...分析記事 • Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jan 07
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Summary Axogen has surged 204% in 12 months, driven by strong sales growth, margin expansion, and efficient capital utilization, offering a favorable risk/reward profile. I get to projected revenues of $280-$350M by FY'26E with NOPAT of $30-$40M, and a valuation range of $22-$28/share, providing 68% upside potential. AXGN's key growth drivers include successful new facility operations, Avance segment progress, and high adoption rates of Axoguard HA and Avive+ products. Read the full article on Seeking Alpha分析記事 • Dec 24
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Despite an already strong run, AxoGen, Inc. ( NASDAQ:AXGN ) shares have been powering on, with a gain of 28% in the...分析記事 • Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$31m |
| Dec 31 2025 | US$9m | US$776k | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$5m |
| Mar 31 2025 | n/a | n/a | -US$7m |
| Dec 31 2024 | US$9m | US$303k | -US$10m |
報酬と市場: Michaelの 総報酬 ($USD 9.05M ) は、 US市場 ($USD 5.26M ) の同規模の企業の平均を上回っています。
報酬と収益: Michaelの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Michael Dale (66 yo)
1.8yrs
在職期間
US$9,047,454
報酬
Mr. Michael D. Dale is Independent Director of CVRx, Inc. from June 1, 2026. Mr. Dale is CEO & Director of AxoGen, Inc. from August 9, 2024 and also serves as its President since 2025. Mr. Dale served as t...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.8yrs | US$9.05m | 0.12% $ 2.7m | |
| Chief Financial Officer | 1.1yrs | US$1.94m | 0.12% $ 2.8m | |
| Executive VP | 3.3yrs | US$3.06m | 0.094% $ 2.1m | |
| Chief Marketing Officer | 3.3yrs | US$2.28m | 0.14% $ 3.1m | |
| Chief Innovation Officer | 2.4yrs | US$2.26m | 0.45% $ 10.2m | |
| Vice President of Operations | no data | データなし | データなし | |
| Vice President of Finance & Investor Relations | no data | データなし | データなし | |
| Vice President of Sales | 4.4yrs | データなし | 0.17% $ 4.0m | |
| Chief Medical Officer | 2.4yrs | データなし | データなし |
2.4yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: AXGNの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.8yrs | US$9.05m | 0.12% $ 2.7m | |
| Independent Chairman of the Board | 5.8yrs | US$242.06k | 0.019% $ 431.3k | |
| Member of Board of Advisor | no data | データなし | データなし | |
| Member of Board of Advisor | no data | データなし | データなし | |
| Independent Director | 4.9yrs | US$217.49k | データなし | |
| Independent Director | 2.5yrs | US$212.66k | データなし | |
| Independent Director | 7.1yrs | US$217.49k | 0.069% $ 1.6m | |
| Independent Lead Director | 9.8yrs | US$224.99k | 0.18% $ 4.0m | |
| Independent Director | 3.9yrs | US$224.99k | 0.00019% $ 4.3k | |
| Independent Director | 3.5yrs | US$209.99k | 0% $ 0 |
4.4yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: AXGNの 取締役会 は 経験豊富 であると考えられます ( 4.4年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/10 15:40 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Axogen, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |